1 |
Neumann J, Hofmann B, Dhein S, Gergs U. Role of Dopamine in the Heart in Health and Disease. Int J Mol Sci 2023;24. [PMID: 36902474 DOI: 10.3390/ijms24055042] [Reference Citation Analysis]
|
2 |
Boutin JA, Leprince J. Why Search for Alternative GPCR Agonists? Receptors 2023;2:16-33. [DOI: 10.3390/receptors2010002] [Reference Citation Analysis]
|
3 |
Legros C, Rojas A, Dupré C, Brasseur C, Riest-Fery I, Muller O, Ortuno JC, Nosjean O, Guenin SP, Ferry G, Boutin JA. Approach to the specificity and selectivity between D2 and D3 receptors by mutagenesis and binding experiments part I: Expression and characterization of D2 and D3 receptor mutants. Protein Sci 2022;31:e4459. [PMID: 36177735 DOI: 10.1002/pro.4459] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
4 |
Chovar-Vera O, López E, Gálvez-Cancino F, Prado C, Franz D, Figueroa DA, Espinoza A, Figueroa C, Lladser A, Pacheco R. Dopaminergic Signalling Enhances IL-2 Production and Strengthens Anti-Tumour Response Exerted by Cytotoxic T Lymphocytes in a Melanoma Mouse Model. Cells 2022;11. [PMID: 36428964 DOI: 10.3390/cells11223536] [Reference Citation Analysis]
|
5 |
Myslivecek J. Multitargeting nature of muscarinic orthosteric agonists and antagonists. Front Physiol 2022;13:974160. [DOI: 10.3389/fphys.2022.974160] [Reference Citation Analysis]
|
6 |
Laskowska AK, Kleczkowska P. Anticancer efficacy of endo- and exogenous potent ligands acting at dopaminergic receptor-expressing cancer cells. Eur J Pharmacol 2022;:175230. [PMID: 36027983 DOI: 10.1016/j.ejphar.2022.175230] [Reference Citation Analysis]
|